Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

69.00
+1.832.72%
Post-market: 69.000.00000.00%19:29 EDT
Volume:2.11M
Turnover:143.47M
Market Cap:7.32B
PE:60.40
High:69.90
Open:64.75
Low:62.40
Close:67.17
Loading ...

Is Corcept Therapeutics' Steady Q2 Earnings Shaping Perceptions of Long-Term Consistency for CORT?

Simply Wall St.
·
Yesterday

Corcept Therapeutics’ Earnings Call: Growth Amid Challenges

TIPRANKS
·
Yesterday

Corcept Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
01 Aug

Stock Track | Corcept Therapeutics Plummets 5.42% as Analysts Slash Price Targets

Stock Track
·
01 Aug

Corcept Therapeutics price target lowered to $121 from $131 at Piper Sandler

TIPRANKS
·
01 Aug

Corcept Therapeutics: Buy Rating Backed by Strategic Growth Initiatives and Promising Product Launches

TIPRANKS
·
01 Aug

U.S. RESEARCH ROUNDUP-Alnylam, Amazon, Appfolio

Reuters
·
01 Aug

Corcept Therapeutics Inc : Piper Sandler Cuts Target Price to $121 From $131

THOMSON REUTERS
·
01 Aug

Earnings Flash:(CORT) Corcept Therapeutics Q2 EPS $0.29 Vs. FactSet Est. $0.19

MT Newswires Live
·
01 Aug

Corcept Therapeutics Q2 EPS $0.29 Beats $0.19 Estimate, Sales $194.430M Miss $199.395M Estimate

Benzinga
·
01 Aug

BRIEF-Corcept Therapeutics Q2 EPS USD 0.29

Reuters
·
01 Aug

Corcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome

TIPRANKS
·
31 Jul

Corcept Therapeutics Inc expected to post earnings of 19 cents a share - Earnings Preview

Reuters
·
30 Jul

Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension

TIPRANKS
·
29 Jul

Corcept Therapeutics’ ALS Study: A Potential Game-Changer?

TIPRANKS
·
26 Jul

Corcept Therapeutics Incorporated to Announce Second Quarter Financial Results

Reuters
·
25 Jul

CEO Joseph K. Belanoff Reports Disposal of Common Shares of Corcept Therapeutics Incorporated

Reuters
·
22 Jul

William Guyer, Chief Development Officer, Reports Disposal of Common Shares of Corcept Therapeutics Inc

Reuters
·
22 Jul

Director Daniel N. Swisher Jr. Reports Disposal of Common Shares of Corcept Therapeutics Incorporated

Reuters
·
15 Jul

H.C. Wainwright Remains a Buy on Corcept Therapeutics (CORT)

TIPRANKS
·
14 Jul